Pruritus and Its Association With Cancer and Mortality in Dermatomyositis and Polymyositis: A Nationwide Cohort Study in Taiwan From 2005 to 2022

Background: Pruritus is the most common initial symptom reported by patients with dermatomyositis (DM) and polymyositis (PM). However, there is limited data regarding the impact of pruritus on cancer and mortality in patients with DM and PM. In this study, we aimed to investigate how pruritus is associated with cancer and mortality in patients with DM and PM. Methods: This nationwide, population‐based retrospective cohort study included adult DM and PM patients from Taiwan’s National Health Insurance Research Database between 2005 and 2022. Sex‐ and age‐matched pruritic patients, identified by over 6 weeks of antipruritic medication use, and nonpruritic patients were analyzed. The primary outcome was cancer occurrence or all‐cause mortality. The association between pruritus and these outcomes was estimated using Cox proportional hazards models. Results: Among 919 matched pairs of pruritic and nonpruritic patients, cancer was observed in 19.96% in the long‐term pruritic group (LPG), 14.63% in the short‐term pruritic group (SPG), and 10.34% in the non‐pruritic group (NPG) ( p < 0.0001). All‐cause mortality was documented as 30.37% in the LPG, 29.69% in the SPG, and 37.76% in the NPG ( p < 0.0001). After adjusting for sex, age, and other comorbidities, pruritus was associated with an increased risk of cancer (hazard ratio (HR) 1.708, 95% confidence interval (CI) 1.229–2.374) and a lower risk of all‐cause mortality (HR 0.483, 95% CI 0.409–0.569). Conclusion: This population‐based study revealed that pruritus appeared to be associated with increased risks of cancer and decreased all‐cause mortality. Thus, pruritus may serve as a pragmatic factor for risk stratification and tailored treatment strategies in DM and PM. Cancer screening, particularly for nasopharyngeal and breast cancers in East Asian populations, is recommended for patients with DM or PM, especially those presenting with pruritus. Meanwhile, patients without pruritus may require vigilant management for potentially life‐threatening complications and comorbidities.